# Ion Beam Applications Forms Joint Venture to Produce Radioisotopes for Cancer Treatment

- URL: https://stocks.freetheai.org/news/ion-beam-applications-forms-joint-venture-to-produce-radioisotopes-for-cancer-590cd8
- Published: 2026-10-16T06:00:00Z
- Category: company_news; sentiment: bullish; impact: low
- Symbols: [EURONEXT:IBAB](https://stocks.freetheai.org/symbols/EURONEXT-IBAB)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Ion Beam Applications S.A. (EURONEXT:IBAB) has partnered with Framatome to establish a joint venture named Ekalia. The new entity aims to build industrial manufacturing sites for Astatine-211, a targeted alpha-therapy isotope used in cancer treatments, across Europe and the United States. The initial facility is scheduled to open in Nantes, France, with operational readiness targeted for 2028.

The partnership moves Ion Beam Applications S.A. deeper into the radioisotope supply chain, addressing demand for specialized medical isotopes. By scaling production facilities, Ekalia intends to create a multi-site network to support broader customer adoption of targeted alpha therapies.

Following the French facility, Ekalia plans to establish a pilot production site in the United States. Future developments to monitor include site financing, securing customer supply contracts, obtaining regulatory approvals, and tracking timeline progress toward commissioning.

## Key points

- Ion Beam Applications S.A. and Framatome created a joint venture called Ekalia.
- The joint venture will produce Astatine-211, an alpha-therapy isotope for cancer treatments.
- The first manufacturing facility is planned for Nantes, France, with a target operational date in 2028.
- Ekalia plans to establish a pilot site in the United States and build a broader production network.

## Questions and answers

### What is Ekalia?

Ekalia is a joint venture formed by Ion Beam Applications S.A. and Framatome to build industrial production sites for Astatine-211 across Europe and the United States.

### When will Ekalia start Astatine-211 production?

The joint venture plans to open its first production site in Nantes, France, with operations expected to begin in 2028.

### Where will Ekalia operate?

Ekalia plans to establish production facilities across Europe and the United States, starting with a main site in Nantes, France, followed by a pilot facility in the U.S.